Researchers from Insmed Inc. presented findings on INM-901, a novel synthetic cannabinoid analogue, demonstrating its effects in the 5xFAD mouse model of Alzheimer’s disease. Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline and sensorimotor impairments, with no available treatments that effectively halt disease progression.